Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK,
Office for Rare Conditions, University of Glasgow, Glasgow, UK,
Horm Res Paediatr. 2022;95(4):363-373. doi: 10.1159/000525075. Epub 2022 May 13.
There is wide variation in reported rates of acute adrenal insufficiency (AI)-related adverse events (sick day episodes and adrenal crises) between centres. This study aimed to evaluate the level of consensus on criteria considered essential for defining and managing these events in children with Congenital Adrenal Hyperplasia.
Active users of the International Congenital Adrenal Hyperplasia and International Disorders of Sex Development (I-CAH/I-DSD) Registries (n = 66), non-active users of I-CAH/I-DSD (n = 35), and the EuRRECa e-Reporting Registry (n = 10) were approached to complete an online survey.
Fifty-six centres from 27 countries responded to the survey; the response rates for the three groups were 42 (65%), 11 (31%), and 3 (30%), respectively. Steroid management plans, one to one patient education, and contact details of health care staff were provided by over 90% of centres in high-income countries. All 56 centres advised glucocorticoid stress dosing in the event of fever. Less common indications for sick day dosing included vaccination and mild afebrile intercurrent illness, recommended by 17 (30%) and 9 (16%) centres, respectively. The most frequently reported stress dosing regimens were tripling the total daily dose of hydrocortisone and administering 3 times daily and doubling or tripling the largest daily hydrocortisone dose depending on the nature of the trigger and administering 3 times daily, recommended by 24 (43%) and 21 (38%) centres, respectively. Vomiting was the most common indication for intramuscular hydrocortisone injection, reported by 34 (61%) centres. Over 50% of respondents indicated that essential clinical criteria for adrenal crisis should include fatigue and nausea or vomiting and over 60% indicated that hypotension, hyponatraemia, hyperkalaemia, and clinical improvement following parenteral glucocorticoids were essential criteria. In the event of an adrenal crisis, 47 (84%) reported that the majority of patients were admitted to hospital. For the management of an adrenal crisis, a bolus parenteral injection of hydrocortisone was the most frequently administered medication, reported by 50 (89%) centres.
Although there is variation in the definition and management of AI-related adverse events in children amongst centres, there is also a good level of consensus on specific aspects that can lead to greater benchmarking of care.
在报道儿童急性肾上腺功能不全(AI)相关不良事件(病假发作和肾上腺危象)的发生率方面,各中心之间存在很大差异。本研究旨在评估在患有先天性肾上腺增生症的儿童中,对于定义和管理这些事件的关键标准,不同中心之间的共识水平。
对国际先天性肾上腺增生症和国际性别发育障碍(I-CAH/I-DSD)登记处的活跃用户(n=66)、非活跃用户(n=35)和 EuRRECa 电子报告登记处(n=10)进行了在线调查。
来自 27 个国家的 56 个中心对调查做出了回应;三组的回应率分别为 42(65%)、11(31%)和 3(30%)。在高收入国家,超过 90%的中心提供了类固醇管理计划、一对一的患者教育和医护人员的联系方式。所有 56 个中心均建议在发热时给予糖皮质激素应激剂量。较少见的病假剂量指征包括接种疫苗和轻度无热的偶发疾病,分别有 17(30%)和 9(16%)个中心建议使用。最常报告的应激剂量方案是将氢化可的松的总日剂量增加三倍并每日给药 3 次,或根据触发因素的性质将最大每日氢化可的松剂量加倍或增加三倍并每日给药 3 次,分别有 24(43%)和 21(38%)个中心推荐使用。34(61%)个中心报告呕吐是肌内注射氢化可的松的最常见指征。超过 50%的受访者表示,肾上腺危象的基本临床标准应包括疲劳和恶心或呕吐,超过 60%的受访者表示低血压、低钠血症、高钾血症和静脉用糖皮质激素后临床改善是基本标准。在发生肾上腺危象时,47(84%)个中心报告说大多数患者被收入院。在管理肾上腺危象时,最常使用的药物是静脉注射氢化可的松的推注剂量,有 50(89%)个中心报告使用了这种药物。
尽管各中心在儿童 AI 相关不良事件的定义和管理方面存在差异,但在某些特定方面也存在着很好的共识,这可以促进护理的基准比较。